Denali Therapeutics Inc
NASDAQ:DNLI
Balance Sheet
Balance Sheet Decomposition
Denali Therapeutics Inc
Denali Therapeutics Inc
Balance Sheet
Denali Therapeutics Inc
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
31
|
40
|
218
|
77
|
79
|
507
|
294
|
218
|
127
|
175
|
|
| Cash Equivalents |
31
|
40
|
218
|
77
|
79
|
507
|
294
|
218
|
127
|
175
|
|
| Short-Term Investments |
0
|
139
|
188
|
387
|
336
|
963
|
572
|
1 118
|
907
|
657
|
|
| Total Receivables |
0
|
0
|
1
|
1
|
0
|
6
|
1
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
3
|
3
|
3
|
15
|
15
|
20
|
31
|
36
|
30
|
32
|
|
| Total Current Assets |
33
|
182
|
410
|
481
|
430
|
1 496
|
897
|
1 372
|
1 064
|
864
|
|
| PP&E Net |
3
|
15
|
15
|
25
|
81
|
74
|
70
|
75
|
72
|
126
|
|
| PP&E Gross |
3
|
15
|
15
|
25
|
81
|
74
|
70
|
75
|
72
|
126
|
|
| Accumulated Depreciation |
0
|
2
|
5
|
12
|
12
|
21
|
29
|
37
|
46
|
52
|
|
| Long-Term Investments |
0
|
73
|
61
|
148
|
40
|
33
|
425
|
0
|
0
|
359
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
8
|
3
|
3
|
12
|
13
|
18
|
25
|
|
| Total Assets |
37
N/A
|
271
+639%
|
487
+80%
|
662
+36%
|
553
-16%
|
1 604
+190%
|
1 404
-12%
|
1 460
+4%
|
1 154
-21%
|
1 374
+19%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
2
|
3
|
2
|
3
|
1
|
5
|
3
|
9
|
11
|
|
| Accrued Liabilities |
2
|
6
|
11
|
19
|
24
|
47
|
53
|
67
|
68
|
73
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
|
| Other Current Liabilities |
0
|
1
|
1
|
12
|
19
|
24
|
320
|
294
|
0
|
14
|
|
| Total Current Liabilities |
4
|
9
|
14
|
33
|
45
|
72
|
378
|
364
|
78
|
102
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Other Liabilities |
1
|
7
|
7
|
82
|
113
|
382
|
64
|
54
|
45
|
37
|
|
| Total Liabilities |
4
N/A
|
17
+313%
|
21
+27%
|
115
+451%
|
158
+38%
|
454
+187%
|
442
-3%
|
418
-5%
|
123
-71%
|
144
+18%
|
|
| Equity | |||||||||||
| Common Stock |
49
|
349
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
|
| Retained Earnings |
17
|
104
|
192
|
228
|
426
|
354
|
645
|
971
|
1 116
|
1 539
|
|
| Additional Paid In Capital |
1
|
9
|
657
|
774
|
819
|
1 504
|
1 608
|
2 019
|
2 145
|
2 765
|
|
| Other Equity |
0
|
0
|
0
|
1
|
0
|
0
|
3
|
7
|
1
|
2
|
|
| Total Equity |
33
N/A
|
255
+678%
|
466
+83%
|
547
+17%
|
395
-28%
|
1 151
+191%
|
962
-16%
|
1 042
+8%
|
1 031
-1%
|
1 230
+19%
|
|
| Total Liabilities & Equity |
37
N/A
|
271
+639%
|
487
+80%
|
662
+36%
|
553
-16%
|
1 604
+190%
|
1 404
-12%
|
1 460
+4%
|
1 154
-21%
|
1 374
+19%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
82
|
82
|
88
|
95
|
96
|
121
|
122
|
136
|
138
|
144
|
|